Clinical trials: Cervical Adenocarcinoma
Esophageal Cancer
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving cisplatin and irinotecan hydrochloride together with radiation therapy works in treating patients with esophageal cancer or gastroesophageal junction cancer that can be removed by…
- Trial name
- NCT00316862
- Testing
- cisplatin, irinotecan hydrochloride, therapeutic conventional surgery
- Where
- 24 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Renal Cell Carcinoma, Lung Carcinoma
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment).
- Conditions
- Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
- Trial name
- NCT00026663
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Gynecologic Cancer
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04682431
- Testing
- PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3
- Where
- 17 sites in United States
- Volunteers
- 127 people
- Sponsor
- Ikena Oncology
Thyroid Carcinoma, Thyroid Cancer
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors.
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell)
- Trial name
- NCT04462471
- Testing
- I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dysphagia, Dysplasia
Esophageal Cytology With FISH in Detecting Esophageal Cancer
This clinical trial studies whether esophageal cytology plus fluorescence in situ hybridization (FISH) is equal to or better than esophago-gastro-duodenoscopy (EGD) or upper endoscopy for the early detection of esophageal cancer.
- Conditions
- Dysphagia, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02100189
- Testing
- Cytology Specimen Collection Procedure, Esophagogastroduodenoscopy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Esophageal Cancer
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086996
- Testing
- fluorouracil, oxaliplatin, conventional surgery
- Where
- 143 sites in United States
- Volunteers
- 98 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer, Esophageal Adenocarcinoma
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
Background: The number of patients with esophageal cancer keeps rising. For many patients, a combination of surgery, chemotherapy, and radiation is necessary to completely treat the disease.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms
- Trial name
- NCT03223662
- Testing
- Chemoradiotherapy, Esophagectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Papillary Thyroid Carcinoma
Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?
study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection.
- Trial name
- NCT04336696
- Testing
- Total thyroidectomy and central neck dissection
- Where
- Egypt
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bassem Mohamed Sieda
Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
The purpose of this study is to evaluate the feasibility of complete nerve-sparing type C1 radical hysterectomy in cervical cancer.
- Conditions
- Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma, Malignant Neoplasm of Cervix Stage IB1, Stage IIA1 Cervical Cancer
- Trial name
- NCT02562729
- Testing
- Nerve-Sparing Radical Hysterectomy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Cervical Adenocarcinoma, Human Papillomavirus
HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (HPV) infections.
- Conditions
- Cervical Adenocarcinoma, Human Papillomavirus, Genome-wide Association Study, Whole Exome Sequencing
- Trial name
- NCT03742869
- Testing
- A multi-omics analysis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei Li
Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Trial name
- NCT00625846
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Adenocarcinoma, Esophageal
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown. Although an operation to remove the esophagus is the most common treatment, previous studies have shown that patients live longer when…
- Conditions
- Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
- Trial name
- POWERRANGER (NCT01404156)
- Testing
- (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Dr. Gordon Buduhan
Esophageal Cancer, Squamous Cell Esophagus Cancer
Pembrolizumab in Refractory Advanced Esophageal Cancer
This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab
- Conditions
- Esophageal Cancer, Squamous Cell Esophagus Cancer, Adenocarcinoma Esophagus
- Trial name
- NCT02971956
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer of Stomach, Oesophageal Cancer
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
- Conditions
- Cancer of Stomach, Oesophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma
- Trial name
- ANZ UGI (NCT05804331)
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04693377
- Testing
- Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Cervical Cancer
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00054067
- Testing
- cisplatin, adjuvant therapy, conventional surgery
- Where
- 50 sites in United States, Japan
- Sponsor
- Gynecologic Oncology Group
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7
- Trial name
- NCT02257528
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 331 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
A Study Involving Neoadjuvant Chemoradiotherapy With Hypofractionated Radiotherapy in Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma
An open-label, single-centre, non-randomized, Phase II trial in patients with esophageal adenocarcinoma. This study aims to show that delivering hypofractionated neoadjuvant concurrent chemoradiotherapy is is equally effective as…
- Trial name
- NCT05370144
- Testing
- Hypofractionated radiotherapy
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- AHS Cancer Control Alberta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.